摘要
目的探讨西洛他唑联合坎地沙坦酯分散片对早期2型糖尿病肾病的保护作用及相关机制。方法选取2015年6月～2017年10月在解放军210医院治疗的伴有下肢动脉粥样硬化的早期2型糖尿病肾病患者80例,根据治疗方法不同随机分为坎地沙坦酯分散片治疗组(对照组,40例)和西洛他唑联合坎地沙坦酯分散片治疗组(联合治疗组,40例)。观察两组患者治疗前和治疗12周后尿白蛋白/肌酐比值(UACR)、血浆尿素(BUN)和肌酐(Scr)、血脂以及血浆炎症因子肿瘤坏死因子-α(TNF-α)的变化。结果两组患者治疗前UACR、BUN和Scr、血脂以及血浆TNF-α差异无统计学意义(P> 0.05)。治疗12周后,两组患者尿白蛋白/肌酐比值、血浆TNF-α较治疗前均明显下降(P <0.05),联合治疗组较对照组下降更显著,差异有统计学意义(P <0.01);两组血浆总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)较治疗前均明显下降,差异有统计学意义(P <0.05),联合治疗组高密度脂蛋白胆固醇(HDL-C)较治疗前增高,差异有统计学意义(P <0.05);联合治疗组TG低于对照组(P <0.05),高密度脂蛋白胆固醇高于对照组,差异有统计学意义(P <0.05);两组BUN和Scr与治疗前差异无统计学意义(P> 0.05)。结论西洛他唑联合坎地沙坦酯分散片治疗早期2型糖尿病肾病比单独应用坎地沙坦酯分散片能更明显地减轻炎症、改善脂代谢紊乱、降低尿白蛋白排泄。
Objective To explore the protective effect and related mechanism of cilotazole combined with candesartan dispersible tablets treatment on early type 2 diabetic nephropathy.Methods 80 patients of early type 2 diabetic nephropathy with lower limb atherosclerosis were randomized into two groups:one was control group(40 patients)which had candesartan cilexetil dispersible tablets,and the other was combination treatment group(40 patients)which had cilostazol combined with candesartan cilexetil dispersible tablets.Before and after 12 weeks treatment,urine albumin-to-creatinine ratio(UACR),plasma urea,plasma creatinine,blood lipid,and plasma TNF-αwere investigated.Results After 12 weeks treatment,UACR and plasma TNF-αwere markedly decreased in both groups(P<0.05).UACR and plasma TNF-αin combination group were decreased more than those in control group(P<0.01).Plasma TC,LDL-C and TG were significantly decreased in both groups compared with those before treatment(P<0.05),and HDL-C in the combined treatment group was higher than that before treatment(P<0.05).TG of the combined treatment group was lower than that of the control group(P<0.05),and HDL-C was higher than that of the control group(P<0.05).There were no significant difference in plasma urea and creatinine compared with those before treatment(P>0.05).Conclusion In the treatment of early type 2 diabetic nephropathy,the combination of cilostatin and candesartan dispersible tablets can significantly reduce inflammation,improve lipid metabolic disorders and reduce urinary albumin excretion.
作者
王西安
陈海英
叶盛开
任霞
温洁
Wang Xi-an;Chen Haiying;Ye Shengkai(Department Outpatient,Dalian 14th Cadre Sanatorium,Liaoning Military District,Dalian 116021,China)
出处
《中华保健医学杂志》
2018年第6期498-501,共4页
Chinese Journal of Health Care and Medicine
关键词
西洛他唑
坎地沙坦酯分散片
早期糖尿病肾病
炎症
Cilostazol
Candesartan cilexetil dispersible tablets
Early stage diabetic nephropathy
Inflammation
